Aquestive Therapeutics, Inc. (AQST) Financials
AQST Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 132.1 million | 188.7 million |
| March 31, 2026 | 141.1 million | 175.2 million |
| Dec. 31, 2025 | 160.4 million | 194.1 million |
| Sept. 30, 2025 | 163.6 million | 167.7 million |
AQST Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -9.7 million | 2.9 million |
| March 31, 2026 | -14.9 million | 2.3 million |
| Dec. 31, 2025 | -8.6 million | 1.4 million |
| Sept. 30, 2025 | -12.9 million | 2.8 million |
AQST Net Income
No data available :(
AQST Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 98.5 million | 50.7 million | 8.3 million |
| March 31, 2026 | 110.7 million | 114.1 million | 4.2 million |
| Dec. 31, 2025 | 121.2 million | 115.5 million | 4.3 million |
| Sept. 30, 2025 | 129.1 million | 115.9 million | 4.5 million |
AQST Shares Outstanding
AQST Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 212000 | 4.0 million | 14.1 million | 2.2 million |
| March 31, 2026 | 52000 | 4.2 million | 11.0 million | - |
| Dec. 31, 2025 | 85000 | 3.2 million | 32.8 million | - |
| Sept. 30, 2025 | 235000 | 4.5 million | 15.3 million | - |
AQST Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 13.8 million | 4.0 million |
| March 31, 2026 | 14.4 million | 3.5 million |
| Dec. 31, 2025 | 13.0 million | 5.8 million |
| Sept. 30, 2025 | 12.8 million | 4.5 million |
AQST Revenue by Segment
Graph available only for paid members. Upgrade to see it.
AQST
Price: $4.67
52 week price:
Earnings Per Share: -0.66 USD
Exchange: NGM
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Volume: 208846
Market Capitalization: 570.9 million